New York man sentenced for laundering Medicare fraud proceeds for Russian crime ring; community oncology practices match or beat national cancer survival rates; scientists identify first human antibodies that could treat measles – Morning Medical Update

New York man sentenced for laundering Medicare fraud proceeds for Russian criminal organization

Elnar Zarbailov was arrested in 2024 as he attempted to flee to Azerbaijan.

A Staten Island man has been sentenced to 37 months in prison for laundering nearly $1.5 million in Medicare fraud proceeds on behalf of a transnational criminal organization based in Russia, as part of what the Department of Justice (DOJ) has called the largest health care fraud case it has ever prosecuted.

• Related content: Unmasking $14.6B in health care fraud: Inside the DOJ's largest-ever health care takedown

Elnar Zarbailov, 42, a dual U.S.-Azerbaijani citizen, served as a fixer and money launderer for the organization, which used fraudulent durable medical equipment (DME) companies, fronted by nominee owners armed with false corporate documents, to deposit Medicare reimbursement checks into U.S. bank accounts and funnel the money to shell companies and overseas banks. Zarbailov deposited fraud proceeds from five DME companies and transferred funds to accounts including those located abroad. He was arrested at JFK Airport in September 2024 as he attempted to board a flight to Azerbaijan and pleaded guilty to conspiracy to commit money laundering in October 2025. In addition to his prison sentence, he was ordered to forfeit $1,457,898.

Community oncology practices match or beat national survival benchmarks for two major cancers

A new study found better or comparable overall survival for metastatic breast cancer and lung cancer patients treated at independent community oncology practices.

Patients with metastatic breast cancer and metastatic non-small cell lung cancer treated at community oncology practices had overall survival rates that were consistently better than or comparable to national population benchmarks, according to a new study from the Community Oncology Alliance (COA) analyzed using the Flatiron Health Research Database (FHRD). After adjusting for age, sex, race and cancer subtype, median overall survival for metastatic breast cancer patients at community practices was 46 months, compared with 29 months in the national Surveillance, Epidemiology and End Results (SEER) database; for metastatic non-small cell lung cancer, the figures were 12 months versus 6 months.

Researchers found that higher rates of treatment initiation at community practices likely drove a significant portion of the survival advantage, particularly for breast cancer subtypes where major therapeutic advances have occurred in recent years. The study, funded by the Community Oncology Alliance with support from BioNTech, Gilead, Johnson & Johnson and Pfizer, adds to a growing body of evidence that independent community practices deliver high-quality care to a patient population that includes historically underserved groups.

Scientists map first comprehensive set of human antibodies against measles virus

One antibody reduced measles virus levels in infected animals to undetectable levels, pointing toward a potential treatment for those who cannot be vaccinated.

National Institutes of Health (NIH)-funded researchers have isolated and mapped the first comprehensive group of human antibodies targeting the measles virus, laying the groundwork for a potential measles treatment at a time when cases are rising in the U.S. and globally, according to a study published in Cell Host & Microbe. The team, led by Erica Ollmann Saphire, Ph.D., MBA, of the La Jolla Institute for Immunology, engineered more than 100 individual human monoclonal antibodies from a vaccinated donor and used cryo-electron microscopy to produce the first atomic-resolution maps of human antibodies bound to measles virus proteins.

The findings upend a long-held assumption that protection against measles is driven almost entirely by antibodies targeting the virus's H protein; the study found that antibodies against the F protein can also confer powerful, independent protection. One F protein antibody, designated 4F09, was the most protective in the study, reducing measles virus levels in infected rats to undetectable levels by locking the protein in place and preventing the virus from entering human cells. No approved measles treatment currently exists in the U.S., leaving immunocompromised patients, pregnant women, and infants too young to be vaccinated without options. More than 470,000 measles cases were reported globally in 2024, and the U.S. has seen at least 72 outbreaks since January 2025.